Iron oxide nanoparticles have previously shown promise in human brain tumor imaging and therapeutic research . Related StoriesNew results reveal association between colorectal tumor and melanoma drug treatmentOvarian cancer sufferers with a brief history of oral contraceptive make use of have better outcomesNew RNA test of blood platelets can be used to detect location of cancerIn this research, the investigators covered iron oxide nanoparticles with dextran or numerous kinds of polyvinylalcohols and examined how these particles interacted with various kinds of human brain cells and three-dimensional aggregates of brain cells. The investigators measured cell toxicity and uptake. While none of the covered nanoparticles had been toxic to mind cells or triggered the discharge of molecules that could signal an inflammatory response was happening, that nanoparticles were found by the investigators with a definite coating, known as amino-polyvinylalcohol, were taken up in much greater numbers.Related StoriesBayer Yakuhin receives MHLW approval in Japan for EYLEA Injection to treat RVO patientsLaser eye surgery: a glimpse in to the future – An interview with Professor Dan ReinsteinAlimera Sciences announces outcomes from ongoing study on ILUVIEN’Visiogen immediately provides Abbott Medical Optics with a skilled team of dedicated experts and an entry point into the accommodating IOL market,’ stated Jim Mazzo, senior vice president, Abbott Medical Optics. ‘The innovative Synchrony accommodating IOL expands our different portfolio of cataract treatments and allows Abbott the opportunity to help the more than 1 billion people worldwide experiencing presbyopia.since January 2009 ‘ Synchrony has received CE mark designation and offers been available commercially in European countries.